Federal Register Notice: FDA’s Oncologic Drugs Advisory Committee will meet 7/14, from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. During the morning session, the committee will discuss a Seattle Genetics BLA for Adcetris (brentuximab vedotin) for injection for the proposed indication for treating relapsed or refractory Hodgkin's lymphoma.

During the afternoon session, the committee will discuss a Seattle Genetics BLA for Adcetris (brentuximab vedotin) for treating relapsed or refractory systemic anaplastic large cell lymphoma. Contact Caleb Briggs, (301) 796-9001. To view this notice, click here.